REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/02/2025
Back to search
Official data from USPTO
ARVELLE THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
06/03/2025
Classification
Registered
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
05/17/2019
Registration date
06/02/2020
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/02/2020
Last transaction
06/03/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
27
Owner location
ZUG, CH
Examiner
FLOWERS, JAY
Law office
M30
Current location
TMO LAW OFFICE 112
Mark description
The mark consists of incomplete triangular designs and the wording "ARVELLE THERAPEUTICS" to the right of the design with the word "ARVELLE" above the word "THERAPEUTICS".
Holders and representatives
Holders
ARVELLE THERAPEUTICS INTERNATIONAL GMBH
Arvelle Therapeutics GmbH
Representatives
Allison Strickland Ricketts FROSS ZELNICK LEHRMAN & ZISSU, P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for human use for the treatment of neurological and central nervous system diseasesdisorders and conditions; biologic preparations for medical and therapeutic purposes for the treatment of neurological and central nervous system diseasesdisorders and conditions
Class 42
Scientific and technological servicesmedical researchscientific research and analysis in the fields of pharmaceuticals and biomedicine; pharmaceuticalbiomedical and biological therapeutic research services; research in the fields of pharmaceutical and biologic therapeutic preparationsclinical trials and post-market trials; pharmaceutical research and development; providing scientific research information in the fields of pharmaceuticalsbiomedicineclinical trials and post-market trials; * none of the aforesaid services being offered in the field of wound care *
Class 44
Providing health and medical information; providing information relating to the diagnosticprophylactic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseasesdisorders and conditions; * none of the aforesaid services being offered in the field of wound care *
Publications
History of USPTO decisions and trademark events.
28 publications found
A7OK
AMENDMENT UNDER SECTION 7 - PROCESSED
02/01/2021
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
01/28/2021
PRAM
POST REGISTRATION ACTION MAILED - SEC. 7
01/25/2021
A7OK
AMENDMENT UNDER SECTION 7 - PROCESSED
01/22/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/19/2021
ES7R
TEAS SECTION 7 REQUEST RECEIVED
11/06/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
06/02/2020
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/08/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/17/2020
PUBO
PUBLISHED FOR OPPOSITION
03/17/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/26/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/13/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
02/11/2020
GNSL
LETTER OF SUSPENSION E-MAILED
02/11/2020
CNSL
SUSPENSION LETTER WRITTEN
02/11/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/10/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/10/2020
ALIE
ASSIGNED TO LIE
02/10/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/03/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/03/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/07/2019
GNRT
NON-FINAL ACTION E-MAILED
08/07/2019
CNRT
NON-FINAL ACTION WRITTEN
08/07/2019
DOCK
ASSIGNED TO EXAMINER
08/05/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/05/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/04/2019
NWAP
NEW APPLICATION ENTERED
05/21/2019
Continuous trademark protection
Get notified about every new filing that threatens ARVELLE THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.